Equibles does not estimate personal net worth.
Get an email with a short summary when enGene Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get ENGN alertsRonald H.W. Cooper is recorded as Board Member and CEO at enGene Therapeutics Inc. (ENGN). The newest filing on record that lists Ronald H.W. Cooper as Board Member and CEO at enGene Therapeutics Inc. (ENGN) is dated May 8, 2026. enGene Therapeutics Inc. reported in an 8-K filed July 24, 2024 that Ronald H.W. Cooper was appointed director, effective July 22, 2024. enGene Therapeutics Inc. reported in an 8-K filed July 24, 2024 that Ronald H.W. Cooper was appointed Chief Executive Officer, effective July 22, 2024. The proxy statement of enGene Therapeutics Inc. reports total compensation of $5,758,289 for Ronald H.W. Cooper in fiscal 2025, including a base salary of $700,000. Disclosed compensation is on record for 2 fiscal years. Ronald H.W. Cooper has spoken on 1 investor event across 1 company, most recently for enGene Therapeutics Inc. on September 8, 2026. enGene Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at enGene Therapeutics Inc. includes Ron Cooper (CEO and Board Member), Ronald H. W. Cooper (CEO and Board Member), Ryan Daws (CFO) and 7 others.
“Effective July 22, 2024, the Board of Directors (the “Board”) of enGene Holdings Inc. (the “Company”) appointed Ronald H.W. Cooper as Chief Executive Officer of the Company and as a director of the Company’s Board as part of the Chief Executive Officer succession plan the Company announced on February 14, 2024.”
“Effective July 22, 2024, the Board of Directors (the “Board”) of enGene Holdings Inc. (the “Company”) appointed Ronald H.W. Cooper as Chief Executive Officer of the Company and as a director of the Company’s Board as part of the Chief Executive Officer succession plan the Company announced on February 14, 2024.”
“So, you know, NGene is a public company. We are focused on non-viral gene therapies. So very unique platform that we have. It's a company that's well advanced. Our lead asset, deadly limogene voroplasmide, is a non-viral gene therapy that we are developing for a form of non-muscle invasive bladder cancer.”
SEC 8-K
2024-10-21–present
Start not stated–present
Last confirmed May 8, 2026
Start not stated–present
Last confirmed May 8, 2026
Biotechnology · Healthcare
Board Member, CEO
2024-10-21–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | enGene Therapeutics Inc. (ENGN) | Chief Executive Officer and President | $700,000 | $5,758,289 |
| 2024 | enGene Therapeutics Inc. (ENGN) | Chief Executive Officer and President | $196,951 | $8,433,812 |
